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Clearance Patterns via Rapid On-Bead Detection from a Single Dried Blood Spot
Christine F. Markwalter,1 Lauren E. Gibson,1,2 Lwiindi Mudenda,1,3 Danielle W. Kimmel,1 Saidon Mbambara,4 Philip E. Thuma,4
and David W. Wright1*
1

Department of Chemistry, Vanderbilt University, Nashville, Tennessee; 2Department of Chemistry and Biochemistry, Elizabethtown College,
Elizabethtown, Pennsylvania; 3Rusangu University, Monze, Zambia; 4Macha Research Trust, Choma, Zambia

Abstract. A rapid, on-bead enzyme-linked immunosorbent assay for Plasmodium lactate dehydrogenase (pLDH) and
Plasmodium falciparum histidine-rich protein 2 (HRP2) was adapted for use with dried blood spot (DBS) samples. This
assay detected both biomarkers from a single DBS sample with only 45 minutes of total incubation time and detection
limits of 600 ± 500 pM (pLDH) and 69 ± 30 pM (HRP2), corresponding to 150 and 24 parasites/μL, respectively. This
sensitive and reproducible on-bead detection method was used to quantify pLDH and HRP2 in patient DBS samples from
rural Zambia collected at multiple time points after treatment. Biomarker clearance patterns relative to parasite clearance
were determined; pLDH clearance followed closely with parasite clearance, whereas most patients maintained detectable
levels of HRP2 for 35–52 days after treatment. Furthermore, weak-to-moderate correlations between biomarker concentration and parasite densities were found for both biomarkers. This work demonstrates the utility of the developed
assay for epidemiological study and surveillance of malaria.

INTRODUCTION

is also relevant in the context of malaria elimination. Recently,
two studies have measured Plasmodium falciparum histidinerich protein 2 (HRP2), the primary protein biomarker used to
diagnose malaria, in DBS patient samples. Rogier et al.15 used
their DBS detection method to evaluate the accuracy of
HRP2-based rapid diagnostic tests, and Gibson et al.16
demonstrated the persistence of HRP2 in patient DBS samples after treatment compared with microscopy. Although
both of these studies demonstrated sensitive HRP2 quantitation from DBS, there are several disadvantages of using
HRP2 alone as a diagnostic marker for malaria. First, HRP2
persists in host circulation for several weeks after parasite
clearance, potentially resulting in false-positive results and
unnecessary prescription of antimalarials.17 Second, HRP2 is
only expressed by one of the ﬁve species of malaria known to
infect humans. Third, infections with P. falciparum histidinerich protein 2 (pfhrp2) gene deletions are increasing in prevalence and result in false-negative results on HRP2-only tests,
posing a major challenge for case management.18
To address these disadvantages, we previously developed a
highly sensitive, magnetic bead–based assay that simultaneously captured and sequentially detected Plasmodium lactate dehydrogenase (pLDH) and HRP2 from a single whole
blood sample.19 Because pLDH is a metabolic enzyme required
for parasite survival, it is present during infections from any of
the ﬁve species of malaria known to infect humans.20,21 In addition, pLDH has been shown to clear within days after treatment.22 As such, this simultaneous capture and sequential
detection (SCSD) assay not only distinguishes between falciparum and non-falciparum infections but also differentiates
between active and resolved falciparum infections. In addition,
the lower limit of detection of the SCSD assay, 2.0 parasites/μL
for both pLDH and HRP2, was an order of magnitude improved
over commercially available enzyme-linked immunosorbent
assay (ELISA) kits and would allow for detection of individuals
with asymptomatic or submicroscopic malaria infections.19
In this work, we adapt the previously developed SCSD assay for pLDH and HRP2 to detect these biomarkers from DBS
and apply it to patient samples from rural Zambia. In particular,
the clearance patterns of both biomarkers relative to parasite

Quantitative laboratory measurement of malarial protein
biomarkers helps deﬁne disease prevalence, distribution, and
infection intensities. In the context of malaria elimination,
sensitive detection methods are useful for determining response to interventions on a population level, ensuring that
low-density infections are identiﬁed, and informing the development of improved point-of-care diagnostics. However,
the logistics and biohazard risk of venous whole blood sample
collection, preservation, and transportation from the ﬁeld to
the laboratory often pose challenges to large studies.
Many of these challenges are mitigated by the use of dried
blood spot (DBS) cards for sample collection and preservation.
In this sampling technique, which does not require specialized
skills or equipment, microliter volumes of whole blood collected
from a ﬁnger prick are spotted onto ﬁlter paper cards and allowed
to dry at room temperature. These DBS samples are then easily
stored or shipped, pose little biohazard risk, and result in improved biomarker stability compared with liquid samples.1,2 The
DBS cards are often cost-effective compared with venous whole
blood sample tubes and require no instrumentation to carry out
the minimally invasive collection procedure.3
Because of these advantages, DBS sample cards have
been used extensively in surveillance and epidemiological
studies of malaria. For example, extraction and detection/
sequencing of nucleic acid material from DBS have allowed
for not only malaria detection in symptomatic and asymptomatic patients4–6 but also speciation,7 determination of
parasite diversity,8 identiﬁcation of drug-resistant strains,9,10
and evaluation of rapid diagnostic tests on a population
level.11–13 Dried blood spots have also been used for the detection of antimalarial antibodies for serology-based epidemiological studies.14
Quantitation of malarial protein biomarkers from DBS
samples, although less common than nucleic acid detection,
* Address correspondence to David W. Wright, Department of
Chemistry, Vanderbilt University, Nashville, TN 37235. E-mail: david.
wright@vanderbilt.edu
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clearance are investigated. The high sensitivity of this assay is
ideal for DBS sample analysis because these samples consist
of just a few microliters of whole blood diluted into extraction
buffer. In addition, the total protocol requires only 45 minutes
of total incubation time for quantitation of both biomarkers,
increasing the throughput and information yield per sample.
MATERIALS AND METHODS
Materials. Human whole blood (K3 EDTA) was purchased
from BioreclamationIVT (Hicksville, NY) (catalog no.
HMWBEDTA3). Recombinant HRP2 protein was generously provided by PATH (Seattle, WA). Recombinant
P. falciparum lactate dehydrogenase (rcPfLDH) was purchased from CTK Biotech (San Diego, CA) (Catalog no.
A3005). Plasmodium falciparum D6 strain was cultured in
the laboratory (stock concentration 18,450 parasites/μL or
43,600 parasites/μL). Anti-HRP2 antibodies were purchased
from Abcam (Cambridge, United Kingdom) (ab9203, ab9206,
and ab30384). Anti-pLDH antibodies were purchased from
Vista Diagnostics (Kirkland, WA) (19g7 and 1201). Vista 1201
was conjugated to alkaline phosphatase (1201:AP) using
Abcam ab102850 and to horseradish peroxidase (1201:HRPx)
using Thermo no. 31489. BluePhos® microwell phosphatase
substrate was purchased from KPL (Gaithersburg, MD) (No.
50-88-02), and TMB One was purchased from Promega (Madison, WI) (G7431). Dynabeads® MyOne™ streptavidin T1 beads
were purchased from Life Technologies (Carlsbad, CA) (no.
65601). Immulon 2HB ELISA plates (14-245-61) were purchased
from Fisher Scientiﬁc (Pittsburgh, PA). 903 Protein saver cards
were purchased from GE Healthcare Life Sciences (Marlborough, MA) (10534612). Six-millimeter biopunches were
acquired from Ted Pella Inc. (Redding, CA) (catalog no. 1511160). All other reagents were purchased from either Fisher
Scientiﬁc or Sigma Aldrich (St. Louis, MO). Dried blood spot
extraction was performed with a Fisher Scientiﬁc analog
vortex mixer (02-215-365). Absorbance measurements were
collected on a Biotek Synergy H4 microplate reader (Vanderbilt University) or Biotek ELx808 microplate reader
(Macha Research Trust).
Standardization of D6 P. falciparum culture. Two stocks
of in-house D6 P. falciparum culture (18,450 parasites/μL
and 43,600 parasites/μL) were used in this study. The pLDH
and HRP2 concentrations in the 18,450 parasite/μL stock
were previously reported as 1.3 and 1.7 pM per parasite/μL,
respectively.16,19 In addition, HRP2 in the 43,600 parasites/μL
stock was previously determined to be 2.2 pM per parasite/μL.23
The pLDH concentration of in-house D6 P. falciparum culture (stock 43,600 parasites/μL) was determined to be 4.4 pM
per parasite/μL using a standard well-plate ELISA, N = 6
(Supplemental Text 1).
Dried blood spot preparation and extraction. Dried blood
spot extraction was adapted from a previously reported
method.16 Dried blood spot was prepared by depositing 10 μL of
parasitized whole blood onto Whatman 903 protein saver cards.
The spots were allowed to air-dry for a minimum of 4 hours,
removed using a 6-mm biopsy punch, and placed in 2-mL
microcentrifuge tubes (one spot per tube). Next, 200 μL of
phosphate-buffered saline (PBS) with 0.1% Tween-20 (PBST)
was added to each tube. The tubes were vortexed at 3,200 rpm
for 10 minutes and then placed in a mini-centrifuge for 30–60
seconds. The supernatant was removed and saved for analysis.

Bead preparation. Anti-pLDH and anti-HRP2 beads were
prepared as reported previously.19,24 Brieﬂy, anti-pLDH (Vista
19g7) or anti-HRP2 (Abcam ab9203) was biotinylated with
EZ-Link NHS–PEG4–Biotin, No-Weigh Format (Thermo no.
21329). Unreacted NHS–PEG4–Biotin was removed using 7K
MWCO Zebra spin desalting columns (Thermo no. 89882).
Next, 5 mg of Dynabeads MyOne streptavidin T1 was washed
three times with PBS and incubated with 500 μL of 0.4 mg/mL
biotinylated antibody in PBS for 30 minutes. The beads were
then washed before incubating in excess D-biotin in PBS
for 30 minutes. Finally, the beads were washed and resuspended in 500 μL of PBS with 0.01% Tween-20. Stock
solutions of antibody-functionalized beads were transported
to Zambia in ambient conditions and stored at 4°C on arrival.
Simultaneous capture and sequential detection ELISA
with DBS extracts. The SCSD ELISA on DBS extracts was
adapted from the previously reported method.19 To avoid
bead aggregation, a low-resource–ﬁltering method was devised for removing small ﬁbers and paper pieces from DBS
extracts (Figure 1). Nylon fabric (Walmart, Bentonville, AK, No
Nonsense Knee Highs) was cut to the appropriate size and
taped onto a Fisherbrand ﬂat-bottom PS 96-well plate (no.
12565501). A polymerase chain reaction (PCR) plate with the
bottoms of the wells removed was then taped on top of
the ﬂat-bottom plate such that the nylon fabric was taut across
the bottom of each well, forming a nylon ﬁlter between the
wells of the ﬂat-bottom and PCR plates. Next, 100 μL of DBS
extract was pipetted through the nylon fabric ﬁlter into the ﬂatbottom plate. The nylon fabric and PCR plate were removed,
and 100 μL of 10% nonfat dried milk in PBST was added to
each well, followed by 4 μL of HAMA blocking reagent (Fitzgerald 85R-1001), 10 μL of 19g7-conjugated magnetic beads,
5 μL of ab9203-conjugated magnetic beads, 1.57 μL of 1201:
AP (1.27 mg/mL), and 2 μL of ab30384 (0.1 mg/mL). The plate
was protected from light and incubated on an orbital shaker for
15 minutes. A MagWell™ magnetic separator was used to
remove the supernatant and wash the beads twice, ﬁrst with
200 μL of PBST followed by 100 μL of PBST. On the second
wash, the beads were moved to new wells, and 100 μL of
BluePhos microwell phosphatase substrate was added to each
well. The plate was protected from light and incubated for
15 minutes. The absorbance of the supernatant was measured
at 620 or 630 nm (pLDH detection). Next, the beads were washed
three times (100 μL PBST) and moved to new wells on the last
wash before being resuspended in 100 μL TMB One solution and
incubated for 5 minutes. The supernatant was then removed and
the reaction was quenched with 100 μL of 2 M H2SO4. Absorbance was measured at 450 nm for detection of HRP2.
Stability study. Dried blood spots were prepared and
stored in Ziploc bags containing the desiccant at room temperature (up to 8 days) and −20°C (up to 188 days). At varying
time points, DBSs were removed from storage and analyzed
using the SCSD ELISA for pLDH and HRP2.
Study setting. Patient DBS samples were collected from
the Nchelenge district of Zambia as part of a separate study on
parasite clearance rates in children less than 5 years of age
presenting with uncomplicated malaria at a local clinic. These
de-identiﬁed samples were made available to the authors for
assessment of pLDH and HRP2 clearance patterns relative to
parasite clearance rates using the DBS SCSD ELISA.
Patient recruitment and ethics. Children at the clinic who
tested positive for malaria (SD Bioline Pf) were recruited for
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FIGURE 1. (A) Affordable 96-well plate ﬁlter for use in low-resource settings. (B) Filtering improved the performance of both the Plasmodium
lactate dehydrogenase (pLDH) and Plasmodium falciparum histidine-rich protein 2 (HRP2) portions of the dried blood spot simultaneous capture
and sequential detection ELISA. This ﬁgure appears in color at www.ajtmh.org.

this study only if a parent or guardian provided written informed consent. The samples were collected under institutional review board approval TDRC/C4/09/2014 and
after approval was granted by the Zambian National Health
Research Authority (MH/101/17/6).
Patient samples. Finger-prick blood samples were collected on protein saver 903 cards. At the time of collection,
parasitemia was determined by thick smear microscopy;
parasites were counted per 200 white blood cells (WBC) and
parasite levels were determined using an estimate of 8,000
WBC/μL. Samples were collected between December 2014
and August 2015, stored at −20°C, and analyzed by SCSD
ELISA in July 2016. Patients were enrolled in the study and
received treatment with artemether–lumefantrine (Coartem®)
after malaria diagnosis by SD Bioline Pf RDT and conﬁrmation
of infection by thick smear. Samples (DBS and thick smears)
were then collected at 15 time points after treatment: 0, 6, 12,
18, 24, 30, 36, 42, and 48 hours as well as 3, 7, 14, 21, 28, and
35 days. Samples for all time points for 15 patients were analyzed in this study.
Patient DBS sample SCSD ELISA. All patient samples
were coded, and the assays were carried out blinded to microscopy results. Patient DBS samples were extracted and
analyzed via the SCSD ELISA as described previously with the
following exceptions: 1) the standard curve (0–400 parasites/μL
from 18,450 parasites/μL stock: 0–520 pM pLDH, 0–680 pM
HRP2) consisted of 1:19 (v:v) parasitized whole blood diluted
in PBST, mimicking the matrix of DBS extract, and 2) if the
signal for either pLDH or HRP2 was above the linear range of
the assay, the DBS extract was reanalyzed at the appropriate
dilution.
Data analysis. Biomarker concentrations in DBS extracts
were interpolated from best ﬁts of linear standard curves. All
error bars shown are the standard error of measurement.
Limits of detection were calculated as the biomarker

concentration at sblank + 3SDblank. Intra-assay variation (%CV)
was determined as the average relative standard deviation
of triplicate measurements on a single plate. Inter-assay
variation (%CV) was determined by ﬁnding the standard
deviation of all measurements at a given concentration on
different days and dividing by the average absorbance measurement at that concentration. For analysis of clearance
rates across all patients, biomarker concentrations were
normalized to their highest value across all time points for
each patient.
RESULTS AND DISCUSSION
Dried blood spot SCSD ELISA optimization. The protocol
for the DBS sample SCSD ELISA was optimized systematically. Optimum conditions for HRP2 recovery from DBS were
previously reported.16 To determine whether this method
achieved sufﬁcient elution of pLDH, the recoveries of both
biomarkers were compared across multiple extraction times in
PBST. The pLDH extraction efﬁciencies were not signiﬁcantly
different from those of HRP2 across all DBS extraction incubation times. In addition, increasing time did not result in
signiﬁcant differences in recoveries for either biomarkers
(Supplemental Figure 1).
Once the DBS samples were extracted, the eluents were
ﬁltered to reduce nonspeciﬁc signal due to bead aggregation
around small ﬁbers and pieces of paper. To accomplish this,
we developed an affordable, homemade ﬁltering device that
could be used in low-resource settings (Figure 1A). The ﬁlter
consisted of a 96-well PCR plate with the tips of the tubes cut
off. Cheap, commercially available nylon fabric covered the
open bottoms of the PCR plate, which nested directly into a
ﬂat-bottomed 96-well plate. The nylon fabric was discarded
after all samples and standards were ﬁltered into the ﬂatbottomed plate, and the PCR plate was washed in 10%
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bleach, followed by three washes with deionized water, and
reused with fresh nylon fabric for ﬁltering. The total cost of the
ﬁltering device was $0.10/sample, but recycling the PCR plate
decreased ﬁltering costs to as low as $0.012/sample. As
shown in Figure 1B, ﬁltering DBS extracts through this device
reduced nonspeciﬁc background signal by 4-fold for pLDH
and 1.5 times for HRP2, increasing the signal-to-noise ratio
from 1.6 to 3.2 and 3.3 to 4.5, respectively. In addition, ﬁltering
the samples had the beneﬁt of decreasing the variation between repeated measurements for the pLDH portion of the
assay (F test, P = 0.02).
After ﬁltration, the SCSD ELISA was performed on DBS
extracts. The previously reported protocol was performed
directly in lysed whole blood.19 Because DBS extracts are
more dilute than lysed whole blood, blocking conditions for
the assay had to be re-optimized. It was found that adding an
equal volume of 10% nonfat dried milk to DBS extracts
resulted in the highest signal-to-noise ratio (Supplemental
Figure 2A). Magnetic bead volumes and detection antibody
concentrations used in the SCSD ELISA for pLDH and HRP2
were screened in this new matrix, and it was found that the
optimized conditions for these parameters were identical to
those in the original protocol for both biomarkers (Supplemental
Figure 2B and C).
Dried blood spot SCSD ELISA performance. The performance of the DBS SCSD ELISA protocol was evaluated
using DBS made from parasitized whole blood. The assay was
performed in triplicate once per day for 3 days (Figure 2). The
linear range of the assay was found to be 0.6–18 nM for pLDH
and 0.15–9.5 nM for HRP2. The intra-assay variation was
10.5% for pLDH and 4.7% for HRP2. The inter-assay variation
was 12.5% for pLDH and 16.9% for HRP2. All four %CV values demonstrate acceptable reproducibility. The limits of
detection were 600 ± 500 pM pLDH and 69 ± 30 pM HRP2,
corresponding to 150 and 24 parasites/μL in our in-house
culture, respectively. It is important to note that these lower
limits are reported as the biomarker concentrations in the
original whole blood sample that was spotted onto the DBS
card. Thus, the inherent dilution associated with DBS extraction and DBS extraction efﬁciency are taken into account.
Although intended for laboratory use, the performance of the
DBS SCSD ELISA was equal to or better than that of currently
available malaria rapid diagnostic tests.
Biomarker detectability over time. Dried blood spot cards
are designed for long-term storage and preservation of biological samples. However, it has been shown that biomarker

detectability from DBS changes over time.16,25 Thus, we
measured pLDH and HRP2 signals from negative and positive
(0 and 1,000 parasites/μL) DBS stored at both −20°C and
room temperature over time. As shown in Supplemental
Figure 3, neither pLDH nor HRP2 signal signiﬁcantly changed
after 6 months of storage at –20°C. However, for both biomarkers, recovery dramatically dropped over time when
stored at room temperature. The pLDH signal at day 8 was
reduced to 35% of the signal on day 0 and HRP2 signal was
reduced to 31% in the same time period. This signal loss could
be due to protein breakdown and loss of structure over time or
to reduced extraction efﬁciency off the DBS card.
Patient DBS samples from rural Zambia. Dried blood spot
samples were collected over 15 time points after treatment of
15 patients; in total, 225 DBSs were analyzed for this study.
Parasitemias at each time point were determined by microscopy at the time of collection. Because DBS patient samples
were 1–2 years old when analyzed, it was not assumed that the
extraction efﬁciency of these patient samples would be the
same as that of freshly prepared DBS standards. Thus, rather
than comparing patient DBS to a standard curve of freshly
prepared DBS to determine biomarker concentrations in the
original whole blood sample that was spotted onto the card,
biomarker concentrations in extracts were determined. This
was performed at Macha Research Trust using standard
curves in parasitized whole blood diluted 1:19, approximating
the DBS extract matrix. Several assays were performed each
day over the course of 2 weeks (N = 14). The intra-assay variation was 9.2% for pLDH and 6.1% for HRP2 and the interassay variation was 19.2% and 24.5% for pLDH and HRP2,
respectively. Linear ranges for the assay were 10–520 pM
pLDH and 10–680 pM HRP2. The limit of detection for the
pLDH portion of the assay was 9 ± 6 pM, corresponding to six
parasites/μL in our in-house culture. The detection limit for
HRP2 was 7 ± 6 pM, which corresponds to four parasites/μL.
These detection limits were used as cutoff values for determination of positive patient samples.
The relationships between biomarker concentrations and
parasite levels for both pLDH and HRP2 based on all DBS
patient samples analyzed in this study are shown in Figure 3.
Similar to previous reports, HRP2 concentrations were several
orders of magnitude higher than pLDH concentrations.26
Weak-to-moderate, but signiﬁcant (P < 0.001), positive correlations with parasitemia were observed for both biomarkers.
The Spearman correlation coefﬁcient was 0.36 (0.23–0.47) for
pLDH and parasitemia and 0.46 (0.36–0.57) for HRP2 and

FIGURE 2. Standard curves for dried blood spot on-bead simultaneous capture and sequential detection ELISA for (A) Plasmodium lactate
dehydrogenase (pLDH) and (B) histidine-rich protein 2 (HRP2).
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FIGURE 3. Correlations between (A) Plasmodium lactate dehydrogenase (pLDH) and parasitemia and (B) histidine-rich protein 2
(HRP2) and parasitemia in patient samples from rural Zambia. Weak
correlations between biomarker concentrations and parasite burdens
were observed. Note: for many data points, error bars are smaller than
the size of the symbol representing the mean value.

parasitemia, demonstrating the utility of these biomarkers for
malaria diagnosis. The nonparametric Spearman correlation
coefﬁcient was chosen because the parasite densities and
concentrations measured do not follow normal distributions
(D’Agostino and Pearson normality tests, P < 0.001). For
pLDH, direct correlations with parasitemia have been demonstrated in the literature for both P. falciparum and Plasmodium vivax malaria.26–28 The strength of the correlation found
in this study is lower than that in some reports, possibly because of the lack of controlled DBS storage conditions after
sample collection. Previous reports have shown that uncontrolled DBS storage can lead to reduced pLDH recovery in
mock patient samples.25 Similarly, we found that DBS storage
at room temperature resulted in a drastic reduction of pLDH
detectability, potentially explaining why DBS from seven patients with high initial parasitemia had initial pLDH levels near
or below the detection limit of the DBS SCSD ELISA. However,
biological factors, such as parasite life cycle stage, also affect
pLDH expression, potentially inﬂuencing the strength of the
observed correlation.29
Many studies have shown correlation between HRP2 and
parasitemia, although some have found no correlation.16,26,30
While uncontrolled storage conditions have a similar detrimental impact on HRP2 detectability as for pLDH, initial HRP2
concentrations were detectable for all patients in this study.
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However, HRP2 expression has been shown to vary with
parasite stage and strain.31,32 In addition, the duration of infection and persistence of HRP2 in circulation, addressed in
detail in the next section, likely inﬂuenced the strength of the
correlation between biomarker concentration and parasite
density.
Biomarker clearance. Unique parasite and biomarker
clearance patterns were observed for each patient. Figure 4
shows clearance rates for three representative patients and
Supplemental Figure 4 shows clearance rates for the
remaining 12 patients. Overall, for the 15 patients in this
study, the median parasite clearance time by microscopy
after treatment with artemether–lumefantrine was 30 hours
(interquartile range: 24–36 hours). Clearance times for the
biomarkers were determined as the ﬁrst time point in which the
biomarker was undetectable for that time point and all subsequent time point measurements. The median pLDH clearance time was 36 hours (interquartile range: 6–72 hours) after
treatment, following closely with parasite clearance time. In
contrast, 13 of the 15 patients (87%) had measurable HRP2
levels at the ﬁnal time point of this study (35–52 days after
treatment). It should be noted that ﬁve of the 13 patients (38%)
who were HRP2 positive at the last time point had undetectable HRP2 levels at least once at a previous time point. It is
possible that uncontrolled storage conditions may have
contributed to the undetectable HRP2 levels in the earlier time
points. However, for one patient, pLDH levels also increased
at the ﬁnal time point, indicating possible reinfection or recrudescence (Supplemental Table 1, Patient 30).
The relationship between intensity of infection and biomarker persistence was also investigated. Patient infection
levels were classiﬁed based on initial parasitemias: low
(0–14,999 parasites/μL, N = 7), medium (15,000–74,999 parasites/μL, N = 5), and high (³ 75,000 parasites/μL, N = 3). Using
a one-way ANOVA (df = 12), there were no signiﬁcant differences in parasite clearance time (P = 0.4221), pLDH clearance
time (P = 0.5543), or HRP2 clearance time (P = 0.3206) across
all three groups.
The overall clearance patterns for all patients are represented in Figure 5. For each patient, parasite and biomarker
levels were normalized to the highest concentration measured. The average across all patients at each time point was
calculated and plotted, allowing for a clear visualization of
the overall parasite, pLDH, and HRP2 clearance patterns in
this study. In general, pLDH became undetectable before
infections became submicroscopic. In contrast, HRP2
remained in circulation for the duration of the study, decreasing in concentration slowly over time. The persistence
and accumulation of HRP2 in circulation over the duration of
an infection likely explain why HRP2 concentrations were
signiﬁcantly higher than pLDH concentrations for all patients
in this study.
In the context of malaria elimination, an ideal evaluation tool
would be positive when a patient has an active infection and
negative in the absence of parasites. Distinguishing between
falciparum and non-falciparum infections would also be clinically useful and inform treatment and provide useful epidemiological data. A sensitive dual pLDH and HRP2 detection
method could fulﬁll these ideals; however, this work highlights
the challenges of developing a dual assay. Although pLDH
detection could overcome the lack of speciﬁcity of HRP2 that
results from persistence in host circulation after parasite
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FIGURE 4. Biomarker clearance trends for three representative patients collected over 35 days. Plasmodium lactate dehydrogenase (pLDH) (top,
solid) and histidine-rich protein 2 (HRP2) (bottom, solid) in dried blood spot extract and parasitemia (dashed) are plotted against time for (A) Patient
29, (B) Patient 55, and (C) Patient 58.

clearance, the relatively low levels of circulating pLDH mean
that active infections could be missed in the dual format. Such
a result would undermine malaria elimination efforts, allowing
active infections to persist and contribute to transmission.
In contrast, an HRP2-only diagnostic could result in overdiagnosis and treatment, potentially resulting in unnecessary
costs and a failure to treat other serious illnesses. Thus, there
is a pressing need to develop more sensitive molecular recognition elements and detection methods for pLDH.
The previously developed SCSD ELISA ﬁlls this need and is
an order of magnitude more sensitive than commercially
available ELISA kits for both pLDH and HRP2.19 Here, the
assay was adapted for detection of both biomarkers from a
single DBS. Uncontrolled DBS storage conditions and the
inherent dilution when DBSs are extracted into buffer contributed to reduced analytical sensitivity of the assay, although
detection limits of the DBS SCSD ELISA remain comparable to
that of commercially available ELISA kits for pLDH and HRP2
applied to whole blood samples. In contrast to commercially
available ELISA kits, which are singleplex and take 3–6 hours
to complete, the SCSD ELISA is capable of detecting two
biomarkers from a single DBS in less than 1 hour. In addition,
the ease with which the antibody-functionalized beads were

transported to Zambia and the possibility of lyophilizing the
beads for stable ambient storage could allow the developed
assay to be applied in laboratories in low-resource settings.
Thus, the DBS SCSD ELISA has the potential to increase the
throughput and information yield of large epidemiological or
surveillance studies based on DBS samples. To this end, we
have demonstrated the utility of this assay for the evaluation of
biomarker clearance in a patient population from rural Zambia.
In the future, the DBS SCSD ELISA will be useful for the
characterization of clearance patterns in other populations
and could also serve as a rapid, preliminary screening tool for
parasites with pfhrp2 deletions.
CONCLUSION
In this work, the on-bead SCSD ELISA for pLDH and HRP2
was adapted for use with DBS samples. For mock DBS samples, the assay was highly reproducible and could detect pLDH
as low as 600 ± 500 pM and HRP2 as low as 69 ± 30 pM,
corresponding to 150 and 24 parasites/μL in our in-house
culture, respectively. Using the DBS SCSD ELISA, we demonstrated the need for controlled DBS storage; the detectability
of both pLDH and HRP2 from DBS decreased nearly 70% after

FIGURE 5. Normalized parasite, Plasmodium lactate dehydrogenase (pLDH), and histidine-rich protein 2 (HRP2) clearance patterns plotted over
time.

RAPID pLDH AND HRP2 DETECTION FROM A SINGLE DBS

8 days of storage at room temperature. Next, we applied the
DBS SCSD ELISA to patient DBS samples from rural Zambia
to measure pLDH and HRP2. In these samples, weak-tomoderate correlations between biomarker concentration and
parasite density were found for both biomarkers, and the overall
concentrations of HRP2 were several orders of magnitude
higher than those of pLDH. Finally, biomarker clearance patterns relative to parasite clearance were studied. It was found
that pLDH clearance followed closely with parasite clearance,
whereas 87% of patients had detectable levels of HRP2 for
35–52 days after treatment. This work demonstrated the utility
of the SCSD ELISA for quantifying pLDH and HRP2 from DBS
samples and its potential for future application in epidemiological studies.
Received December 20, 2017. Accepted for publication February 3,
2018.
Published online March 19, 2018.

6.

7.

8.

9.

10.

Note: Supplemental text, ﬁgures and table appear at www.ajtmh.org.
Acknowledgments: First and foremost, we would like to thank the
children and guardians who participated in this study. We also thank
Macha Research Trust for collecting and providing the dried blood
spot patient samples and for the use of their on-site laboratories. We
thank Kim League for culturing the D6 Plasmodium falciparum stocks
used in this work and M. F. Richards for his critical comments in the
preparation of the manuscript.

11.

Financial support: The assay development and sample analysis portions of this work were supported by the National Institute of Health/
Fogarty International Center (D43 TW009348) and Vanderbilt University through Laboratories for Innovation in Global Health Technologies. The clinical portion of the study was supported by the National
Institutes of Health as part of the International Centers of Excellence
for Malaria Research (U19 AI089680). C. F. M. acknowledges support
from the National Science Foundation Graduate Research Fellowship
(1445197). Additional support was provided by Vanderbilt University
through the Mitchum E. Warren, Jr. Graduate Research Fellowship
(L. E. G.).

12.

Authors’ addresses: Christine F. Markwalter, Danielle W. Kimmel, and
David W. Wright, Department of Chemistry, Vanderbilt University,
Nashville, TN, E-mails: christine.markwalter@vanderbilt.edu, danielle.w.
kimmel@vanderbilt.edu, and david.wright@vanderbilt.edu. Lauren E.
Gibson, Department of Chemistry and Biochemistry, Elizabethtown
College, Elizabethtown, PA, E-mail: gibsonlauren@etown.edu. Lwiindi
Mudenda, Rusangu University, Monze, Zambia, E-mail: lwiindimudenda@
yahoo.com. Saidon Mbambara and Philip E. Thuma, Macha Research
Trust, Choma, Zambia, E-mails: saidon.mbambara@macharesearch.org
and phil.thuma@macharesearch.org.

15.

16.

This is an open-access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the
original author and source are credited.

18.

REFERENCES

19.

1. Demirev PA, 2013. Dried blood spots: analysis and applications.
Anal Chem 85: 779–789.
2. Sharma A, Jaiswal S, Shukla M, Lal J, 2014. Dried blood spots:
concepts, present status, and future perspectives in bioanalysis. Drug Test Anal 6: 399–414.
3. Parker SP, Cubitt WD, 1999. The use of the dried blood spot
sample in epidemiological studies. J Clin Pathol 52: 633–639.
4. Wang B et al., 2014. Comparison of microscopy, nested-PCR,
and real-time-PCR assays using high-throughput screening of
pooled samples for diagnosis of malaria in asymptomatic carriers from areas of endemicity in Myanmar. J Clin Microbiol 52:
1838–1845.
5. Singh B, Cox-Singh J, Miller AO, Abdullah MS, Snounou G, Abdul
Rahman H, 1996. Detection of malaria in Malaysia by nested

13.

14.

17.

20.
21.
22.

23.

1395

polymerase chain reaction ampliﬁcation of dried blood spots on
ﬁlter papers. Trans R Soc Trop Med Hyg 90: 519–521.
Hsiang MS, Lin M, Dokomajilar C, Kemere J, Pilcher CD, Dorsey
G, Greenhouse B, 2010. PCR-based pooling of dried blood
spots for detection of malaria parasites: optimization and application to a cohort of Ugandan children. J Clin Microbiol 48:
3539–3543.
Taylor SM, Juliano JJ, Trottman PA, Grifﬁn JB, Landis SH, Kitsa P,
Tshefu AK, Meshnick SR, 2010. High-throughput pooling and
real-time PCR-based strategy for malaria detection. J Clin
Microbiol 48: 512–519.
Searle KM et al., 2017. Distinct parasite populations infect individuals identiﬁed through passive and active case detection in a
region of declining malaria transmission in southern Zambia.
Malar J 16: 154.
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